

b) 0,2 g **7** in 6 ml CH_2Cl_2 werden mit 0,4 g Ag_2O und 0,5 ml CH_3I unter Rühren 1 h erwärmt. Danach werden erneut 0,4 g Ag_2O und 0,5 ml CH_3I zugesetzt. Nach einer weiteren Reaktionsdauer von 1 h wird über eine kurze mit SiO_2 gefüllte Säule filtriert und der Rückstand aus Ethanol kristallisiert, gelbe Nadeln, Schmp. 126–127°. Der Mischschmp. der Kristalle aus a) und b) zeigt keine Depression, die IR-Spektren sind identisch. $\text{C}_{12}\text{H}_{10}\text{O}_3$ (202,0630) Mol.-Masse: 202,0639 (ms).

Literatur

- 1 7. Mitt.: G. Wurm und U. Geres, Arch. Pharm. (Weinheim), im Druck.
- 2 R. H. Thomson, J. Org. Chem. 13, 377 (1948).
- 3 R. H. Thomson, J. Org. Chem. 16, 1082 (1951).
- 4 J. W. McLeod und R. H. Thomson, J. Org. Chem. 25, 36 (1960).
- 5 R. L. Hannan, R. B. Barber und J. Rapport, J. Org. Chem. 44, 2153 (1979).
- 6 G. Wurm, U. Geres und H. Schmidt, Dtsch. Apoth. Ztg. 120, 2045 (1980).
- 7 G. Wurm, U. Geres und H. Schmidt, Arch. Pharm. (Weinheim) 314, 861 (1981).
- 8 L. F. Fieser und J. T. Dunn, J. Am. Chem. Soc. 58, 572 (1936).

[KPh 288]

Arch. Pharm. (Weinheim) 317, 280–282 (1984)

Syntheses of the Leukotrienes C_5 , D_5 , and E_5

Synthese der Leukotriene C_5 , D_5 und E_5

Bernd Spur*, Attilio Crea, Wilfried Peters

Institut für Organische Chemie I und Anorganische Chemie I der Universität Düsseldorf,
Universitätsstr. 1, D-4000 Düsseldorf 1, Federal Republic of Germany



und Wolfgang König

Lehrstuhl für Medizinische Mikrobiologie und Immunologie, Ruhr-Universität Bochum,
Postfach, D-4630 Bochum, Federal Republic of Germany
Eingegangen am 7. November 1983

The leukotrienes recently discovered derivatives of arachidonic acid have rapidly gained recognition as agents of remarkable biological potency in a number of tissues and organ systems. In particular, interest has been devoted to the cysteinyl-containing LTC_4 (**1a**), LTD_4 (**1b**), and LTE_4 (**1c**) apparently representing the biological active components of the "slow reacting substance of anaphylaxis" and, hence, presumed mediators of allergic bronchoconstriction^{1,2)}.






Other leukotrienes are of considerable interest, too. Thus the leukotrienes LTC_5 (**2a**), LTD_5 (**2b**), and LTE_5 (**2c**) formed in vivo from eicosapentaenoic acid via the 5-lipoxygenase pathway are reported to possess biological activities comparable to that of the "natural" leukotrienes³⁾.

Up till now thorough medical studies of these important metabolites were hampered by lack of substance. Only few nanograms could be isolated from biological sources. In this

**1a-c**LTC₄, LTD₄, LTE₄**2a-c**LTC₅, LTD₅, LTE₅

R = glutathione LTC; R = cysteinylglycine LTD; R = cysteine LTE;

paper we wish to report the first chemical synthesis of LTC₅ (**2a**), LTD₅ (**2b**) and LTE₅ (**2c**). As a result of our synthetic work these rare substances are available for the first time in quantities sufficient for biological and medical studies⁴⁾.



1-Bromo-pent-2-yne (**3**)⁵⁾ was converted into 3,5-nonadiyn-1-ol (**4**)⁶⁾ by the method of Eiter⁷⁾ (DBU, CuJ, HMPT, THF, 3-butyne-1-ol). Selective hydrogenation of **4** (Lindlar catalyst, THF, (C₂H₅)₃N) to 3,5-nonadien-1-ol (**5**)⁶⁾ followed by treatment with CBr₄/P(C₆H₅)₃ (CH₂Cl₂, 0°C, 10 min)⁸⁾ led to the corresponding bromide **6** which after further reaction with P(C₆H₅)₃ in acetonitrile under reflux afforded the phosphonium bromide **7** in an over all yield of 20 % (**3-7**).

Generation of the phosphorane **8** (BuLi, THF, HMPT, -78°C) and addition of the dienealdehyde **9**⁹⁻¹¹⁾ (-78°C, 5 min) gave after standard work up (chromatography over SiO₂ in the presence of triethylamine and subsequent HPLC separation) the highly unstable LTA₅ **10** in 30 % yield (UVλ_{max} 270 sh, 280, 291 sh nm)¹²⁾. LTA₅ **10** is readily converted into its isomers by light and air. Instant decomposition is effected by slight traces of acid. Reaction of **10** as previously described¹³⁻¹⁵⁾ with glutathione, cysteinylglycine and cysteine provided the novel LTC₅, LTD₅, LTE₅ monomethyl esters (60 % yield) which were purified by RP-HPLC (CH₃OH/H₂O/CH₃COOH = 65:35:0.01; pH: 6.8). Hydrolysis (0.1 M · K₂CO₃; 12 h) gave the free LTC₅ **2a**, LTD₅ **2b**, LTE₅ **2c** in essentially quantitative yield.

The biological activity of the leukotrienes **2a-c** was determined in the terminal guinea pig ileum. While LTC₅ (**2a**) and LTD₅ (**2b**) exhibit high SRS-activity at concentrations of 1-10 ng LTE₅ (**2c**) is about 40-50 fold less active⁴⁾.

The authors would like to extend their thanks to Dr. W. D. Busse and Dr. M. Mardin, Bayer-Pharma AG Wuppertal, for the financial support of this research.

References

- 1 B. Samuelsson, R. Paoletti and P. W. Ramwell in *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*, Vol. 9, 11, 12, Raven, Press, New York 1982/83.
- 2 B. Samuelsson, *Angew. Chem.* 94, 881 (1982).
- 3 S. Hammarström, *J. Biol. Chem.* 255, 7093 (1980).
- 4 The results of the full biological studies will be reported separately.
- 5 J. Jaenicke and K. Seferiadis, *Chem. Ber.* 108, 225 (1975).
- 6 T. Kajiwara, Y. Odaka and A. Hatanaka, *Agric. Biol. Chem.* 39, 1617 (1975).
- 7 K. Eiter, F. Lieb, H. Disselinkötter and H. Oediger, *Justus Liebigs Ann. Chem.* 1978, 658.
- 8 P. J. Kocienski, G. Cernigliaro and G. Feldstein, *J. Org. Chem.* 42, 353 (1977).
- 9 E. J. Corey, D. A. Clark, G. Goto, A. Marfat, C. Mioskowski, B. Samuelsson and S. Hammarström, *J. Am. Chem. Soc.* 102, 1436 (1980).
- 10 I. Ernest, A. J. Main and R. Menasse, *Tetrahedron Lett.* 1982, 167.
- 11 N. Cohen, B. L. Banner, R. J. Lopresti, F. Wong, M. Rosenberger, Y. Y. Liu, E. Thom and A. A. Liebman, *J. Am. Chem. Soc.* 105, 3661 (1983).
- 12 NMR, IR and MS data were obtained for each stable synthetic intermediate and were in full accord with the assigned structures.
- 13 B. Spur, A. Crea, W. Peters and W. König, *Tetrahedron Lett.* 1983, 2135.
- 14 B. Spur, A. Crea, W. Peters and W. König, *Arch. Pharm. (Weinheim)* 316, 572 (1983).
- 15 B. Spur, A. Crea, W. Peters and W. König, *Arch. Pharm. (Weinheim)* 316, 958 (1983).

[KPh 290]

Arch. Pharm. (Weinheim) 317, 282–284 (1984)

Darstellung von „Dithiophenolphthalein“

Synthesis of "Dithiophenolphthalein"

Paul Messinger

Institut für Pharmazeutische Chemie der Universität Hamburg, Laufgraben 28, 2000 Hamburg 13
Eingegangen am 24. November 1983

3,3-Bis-(4-mercaptophenyl)-phthalid, „Dithiophenolphthalein“ (4) ist unseres Wissens bisher nicht beschrieben. Diese Verbindung interessierte als mögliches stark nucleophiles Chromophor im Zusammenhang mit Untersuchungen über die Reaktivität aktivierter Sulfone¹⁾.

Zur Darstellung von 4 wird Phenolphthalein (1) mit Dimethylthiocarbamoylchlorid (DMTCC) zu Bis-(thiocarbamidsäure-O-arylester) 2 umgesetzt. Dieser isomerisiert in einer *Newman-Kwart-Umlagerung*²⁾ zu Bis-(thiocarbamidsäure-S-arylester) 3, dessen anschließende alkalische Hydrolyse 4 liefert. Ein analoger Reaktionsweg zur Darstellung einfacher Thiophenole ist beschrieben worden^{2,3)}.